282 related articles for article (PubMed ID: 34430382)
1. How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review.
Remon J; Menis J; Levy A; De Ruysscher DKM; Hendriks LEL
Transl Lung Cancer Res; 2021 Jul; 10(7):3486-3502. PubMed ID: 34430382
[TBL] [Abstract][Full Text] [Related]
2. Treatment outcome of patients with synchronous oligometastatic non-small cell lung cancer in the immunotherapy era: Analysis of a real-life intention-to-treat population.
Jongbloed M; Bartolomeo V; Steens M; Dursun S; van de Lisdonk T; De Ruysscher DKM; Hendriks LEL
Eur J Cancer; 2023 Sep; 190():112947. PubMed ID: 37451182
[TBL] [Abstract][Full Text] [Related]
3. Radiation for Oligometastatic Lung Cancer in the Era of Immunotherapy: What Do We (Need to) Know?
Peeters STH; Van Limbergen EJ; Hendriks LEL; De Ruysscher D
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33925139
[TBL] [Abstract][Full Text] [Related]
4. Defining oligometastatic non-small cell lung cancer: concept versus biology, a literature review.
Mentink JF; Paats MS; Dumoulin DW; Cornelissen R; Elbers JBW; Maat APWM; von der Thüsen JH; Dingemans AC
Transl Lung Cancer Res; 2021 Jul; 10(7):3329-3338. PubMed ID: 34430370
[TBL] [Abstract][Full Text] [Related]
5. Radiation and immune checkpoint inhibitors in the treatment of oligometastatic non-small-cell lung cancer: a practical review of rationale, recent data, and research questions.
Zayed S; Louie AV; Breadner DA; Palma DA; Correa RJM
Ther Adv Med Oncol; 2023; 15():17588359231183668. PubMed ID: 37435562
[TBL] [Abstract][Full Text] [Related]
6. Local control strategies for management of NSCLC with oligoprogressive disease.
Mavrikios A; Remon J; Quevrin C; Mercier O; Tselikas L; Botticella A; Nicolas E; Deutsch E; Besse B; Planchard D; Barlesi F; Le Péchoux C; Levy A
Cancer Treat Rev; 2023 Nov; 120():102621. PubMed ID: 37690180
[TBL] [Abstract][Full Text] [Related]
7. The Role of Surgery for Oligometastatic Non-Small Cell Lung Cancer.
Euhus CJ; Ripley TR; Medina CG
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626125
[TBL] [Abstract][Full Text] [Related]
8. Changing equipoise in the landscape of radiation for oligometastatic lung cancer.
Schroeder SR; Leenders M; Iyengar P; de Ruysscher D
Transl Lung Cancer Res; 2019 Sep; 8(Suppl 2):S184-S191. PubMed ID: 31673523
[TBL] [Abstract][Full Text] [Related]
9. Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials.
Izmailov T; Ryzhkin S; Borshchev G; Boichuk S
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958408
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer.
Wang P; Yin T; Zhao K; Yu J; Teng F
J Cancer Res Clin Oncol; 2022 May; 148(5):1253-1261. PubMed ID: 34812931
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy for oligometastatic non-small cell lung cancer: a narrative review.
Sundahl N; Lievens Y
Transl Lung Cancer Res; 2021 Jul; 10(7):3420-3431. PubMed ID: 34430377
[TBL] [Abstract][Full Text] [Related]
12. Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery.
Boch T; Frost N; Sommer L; Overbeck TR; Michaeli CT; Szuszies CJ; Rieckmann LM; Beumer N; Imbusch CD; Winter H; Thomas M; Roeper J; Janning M; Griesinger F; Wermke M; Loges S
Lung Cancer; 2022 Feb; 164():46-51. PubMed ID: 34998106
[TBL] [Abstract][Full Text] [Related]
13. Current and future research efforts in oligometastatic non-small cell lung cancer-a systematic review.
Brandão M; Durieux V; Berghmans T
Transl Lung Cancer Res; 2021 Jul; 10(7):3473-3485. PubMed ID: 34430381
[TBL] [Abstract][Full Text] [Related]
14. Oligometastatic non-small cell lung cancer: Current management.
Román-Jobacho A; Hernández-Miguel M; García-Anaya MJ; Gómez-Millán J; Medina-Carmona JA; Otero-Romero A
J Clin Transl Res; 2021 Jun; 7(3):311-319. PubMed ID: 34239990
[TBL] [Abstract][Full Text] [Related]
15. A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer.
Akanda ZZ; Neeson PJ; John T; Barnett S; Hanna GG; Miller A; Jennens R; Siva S
Transl Lung Cancer Res; 2021 Jun; 10(6):2766-2778. PubMed ID: 34295676
[TBL] [Abstract][Full Text] [Related]
16. Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy.
Dohopolski M; Iyengar P
Ann Palliat Med; 2021 May; 10(5):5944-5953. PubMed ID: 33691460
[TBL] [Abstract][Full Text] [Related]
17. Oligometastatic Disease in Non-Small-Cell Lung Cancer: An Update.
Chen YH; Ho UC; Kuo LT
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267658
[TBL] [Abstract][Full Text] [Related]
18. The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review.
Berzenji L; Debaenst S; Hendriks JMH; Yogeswaran SK; Lauwers P; Van Schil PE
Transl Lung Cancer Res; 2021 Jul; 10(7):3409-3419. PubMed ID: 34430376
[TBL] [Abstract][Full Text] [Related]
19. A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done.
Belluomini L; Dodi A; Caldart A; Kadrija D; Sposito M; Casali M; Sartori G; Ferrara MG; Avancini A; Bria E; Menis J; Milella M; Pilotto S
Transl Lung Cancer Res; 2021 Jul; 10(7):3369-3384. PubMed ID: 34430373
[TBL] [Abstract][Full Text] [Related]
20. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
